Effect of Xuezhikang, an Extract From Red Yeast Chinese Rice, on Coronary Events in a Chinese Population With Previous Myocardial Infarction
Top Cited Papers
- 15 June 2008
- journal article
- research article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 101 (12), 1689-1693
- https://doi.org/10.1016/j.amjcard.2008.02.056
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Efficacy and safety of Monascus purpureus Went rice in subjects with hyperlipidemiaActa Endocrinologica, 2005
- Effects of Xuezhikang, an extract of cholestin, on lipid profile and C-reactive protein: a short-term time course study in patients with stable anginaClinica Chimica Acta; International Journal of Clinical Chemistry, 2005
- Xuezhikang, an Extract of Cholestin, Protects Endothelial Function Through Antiinflammatory and Lipid-Lowering Mechanisms in Patients With Coronary Heart DiseaseCirculation, 2004
- Xuezhikang Decreases Serum Lipoprotein(a) and C-reactive Protein Concentrations in Patients with Coronary Heart DiseaseClinical Chemistry, 2003
- Effect of xuezhikang, a cholestin extract, on reflecting postprandial triglyceridemia after a high-fat meal in patients with coronary heart diseaseAtherosclerosis, 2003
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsThe New England Journal of Medicine, 1998
- Multicenter clinical trial of the serum lipid-lowering effects of a Monascus purpureus (red yeast) rice preparation from traditional Chinese medicineCurrent Therapeutic Research, 1997
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsThe New England Journal of Medicine, 1996
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994